

-1-

METHOD FOR EVALUATING PATIENTS FOR TREATMENT WITH DRUGS TARGETING RET RECEPTOR TYROSINE KINASE

The present invention relates to a method of selection of a patient, who is a candidate for treatment with a RET drug, whereby to predict an increased likelihood of response to a RET drug. The invention provides a method for determining the sequence of RET. The method provides ARMS primers optimized for determining the sequence of RET. The invention also provides a diagnostic kit, comprising an ARMS primer.

The phosphorylation of proteins on tyrosine residues is a key element of signal transduction within cells. Enzymes capable of catalysing such reactions are termed tyrosine kinases. A number of transmembrane receptors contain domains with tyrosine kinase activity and are classified as receptor tyrosine kinases (RTKs). RTKs transduce extracellular signals for processes as diverse as cell growth, differentiation, survival and programmed cell death. In response to binding of extracellular ligands, RTKs typically dimerise, leading to autophosphorylation and intracellular signal transduction through effectors that recognise and interact with the phosphorylated form of the RTK. There are several members of this family of RTKs, one of which is the RET proto-oncogene which encodes the 120kDa protein RET (Rearranged during Transfection). RET is a receptor for growth factors of the glial-derived neurotrophic factor (GDNF) family. Two ligands for RET have been identified; GDNF and neurturin (NTN). RET is activated when its ligand binds a co-receptor and the complex then interacts with RET (Eng, 1999 Journal Clinical Oncology: 17(1) 380-393).

Activation causes RET to become phosphorylated on tyrosine residues, leading to transduction of signals for cell growth and differentiation through the RAS-RAF and the PI3 kinase pathways and possibly additional routes.

Point mutations that activate RET are known to cause three related, dominantly inherited cancer syndromes; multiple endocrine neoplasia type 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma (FMTC) (Santoro et al. 2004 Endocrinology: 145, 5448-5451)

In nearly all MEN2A cases and some FMTC cases there are substitutions of cysteines in the extracellular, juxtamembrane cysteine-rich domain, whereas 95% of MEN2B cases are the result of a single point mutation at codon 918 in the kinase domain (M918T). Codon 918 is thought to be located in the substrate recognition pocket of the catalytic core. Mutation at this site is thought to alter the structure of the activation loop of the RET catalytic domain, thereby

-2-

constitutively activating RET. The M918T mutation is also found in sporadic medullary carcinomas, in which it correlates with an aggressive disease phenotype. *In vitro* studies have shown that the mutation affects substrate specificity, such that RET recognises and phosphorylates substrates preferred by non-receptor tyrosine kinases such as c-src and c-abl
5 (Eng et al. 1996 JAMA: 276, 1575-1579; Ponder et al. 1999 Cancer Research: 59, 1736-1741; Schilling et al. 2001 International Journal of Cancer: 95, 62-66; Santoro et al. 1995 Science: 267, 381-383; Zhou et al. 1995 Nature: 273, 536-539).

As mutations in the RET gene have been identified in the majority of MEN2 families, molecular diagnostic testing is possible, and can be useful to confirm a clinical diagnosis.
10 Testing for RET mutations can be performed using polymerase chain reaction-based protocols; wherein target exonic sequences are amplified for direct sequencing or restriction endonuclease digestion (Zhong et al. 2006 Clinica Chimica Acta: 364, 205-208).

Another member of the family of RTKs is vascular endothelial growth factor receptor 2 (VEGFR2 (the kinase insert domain-containing receptor, KDR (also referred to as Flk-1))).
15 VEGFR2 is a receptor for vascular endothelial growth factor (VEGF). VEGF is believed to be an important stimulator of both normal and disease-related angiogenesis (Jakeman, et al. 1993 Endocrinology: 133,848-859; Kolch, et al. 1995 Breast Cancer Research and Treatment: 36,139-155) and vascular permeability (Connolly, et al. 1989 J. Biol. Chem: 264,20017-20024). Antagonism of VEGF action by sequestration of VEGF with antibody can result in
20 inhibition of tumour growth (Kim, et al. 1993 Nature: 362,841-844). Heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularisation (Carmeliet, et al. 1996 Nature 380:435-439; Ferrara, et al. 1996 Nature 380:439-442).

Binding of VEGF to VEGFR2 leads to receptor dimerisation, causing VEGFR2 autophosphorylation of specific intracellular tyrosine residues. Autophosphorylation
25 increases the catalytic activity of the tyrosine kinase and provides potential docking sites for cytoplasmic signal transduction molecules such as phospholipase C- γ . These protein interactions mediate the intracellular signaling necessary to induce cellular response to VEGFR2, for example endothelial cell proliferation, survival and migration (Ryan et al. 2005 British Journal Cancer: 92(Suppl.1) S6-S13).

30 Recognition of the key role of VEGF-mediated VEGFR2 signalling in pathological angiogenesis has led to the development of various selective approaches to inhibit VEGFR2 activation. These include small molecule ATP-competitive tyrosine kinase inhibitors, which

-3-

in preventing ATP binding preclude autophosphorylation and subsequent intracellular signal transduction (Ryan, 2005).

Quinazoline derivatives which are inhibitors of VEGF receptor tyrosine kinase are described in International Patent Applications Publication Nos. WO 98/13354 and
5 WO 01/32651. In WO 98/13354 and WO 01/32651 compounds are described which possess activity against VEGF receptor tyrosine kinase whilst possessing some activity against epidermal growth factor receptor (EGFR) tyrosine kinase.

It has been disclosed (Wedge et al. 2002 Cancer Research: 62, 4645-4655) that the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-
10 ylmethoxy)quinazoline is a VEGFR2 tyrosine kinase inhibitor. This compound is also known as Zactima™ (registered trade mark), by the generic name vandetanib and by way of the code number ZD6474. The compound is identified hereinafter as vandetanib.

Vandetanib was developed as a potent and reversible inhibitor of ATP-binding to VEGFR2 tyrosine kinase. In addition, vandetanib also inhibits EGFR tyrosine kinase activity.
15 The EGFR signalling pathway is also key to cancer progression, where aberrant EGFR activity increases tumour cell proliferation, survival and invasiveness as well as the overexpression of VEGF. Inhibition of EGFR signalling has been shown to induce selective apoptosis in tumour endothelial cells.

In 2002 it was reported that vandetanib had demonstrated potent inhibition of ligand-
20 dependent RET tyrosine kinase activity thereby inhibiting the signalling and transforming capacity of RET. Furthermore, vandetanib demonstrated a strong growth-inhibitory effect on RET-dependent thyroid tumour cell growth *in vitro* (Carlomagno et al. 2002 Cancer Research: 62, 7284-7290). Vandetanib inhibited the majority of mutated, activated forms of RET and also the wild type receptor. Therefore in addition to inhibition of VEGFR2 and EGFR
25 tyrosine kinase, it is thought that inhibition of RET tyrosine kinase by vandetanib may contribute additional antitumour effects in treating tumours with mutations in the RET gene which lead to RET-dependent tumour cell growth (Ryan, 2005).

The present invention permits the selection of a patient, who is a candidate for treatment with a RET drug, in order to predict an increased likelihood of response to a RET
30 drug. As mutations that constitutively activate RET are known to lead to several RET-signaling dependent cancer syndromes, determination of these mutations in a patient can be used to assess the suitability of a patient for treatment with a RET drug.

-4-

According to one aspect of the invention there is provided a method for predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, comprising determining the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 1: position 105, is not thymine. In one
5 embodiment, the method comprises determining whether the sequence of RET in a sample obtained from the patient at position 105, as defined in SEQ ID NO:1, is not thymine, whereby to predict an increased likelihood of response to the RET drug. In one embodiment, the method comprises determining the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 1: position 105, is cytosine. In one
10 embodiment, the method comprises determining whether the sequence of RET in a sample obtained from the patient at position 105, as defined in SEQ ID NO:1, is cytosine, whereby to predict an increased likelihood of response to the RET drug.

According to another aspect of the invention there is provided a method for predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to
15 said treatment, comprising determining the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 2: position 918, is not methionine. In one embodiment, the method comprises determining whether the sequence of RET in a sample obtained from the patient at position 918, as defined in SEQ ID NO:2, is not methionine, whereby to predict an increased likelihood of response to the RET drug. In one
20 embodiment, the method comprises determining the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 2: position 918, is threonine. In one embodiment, the method comprises determining whether the sequence of RET in a sample obtained from the patient at position 918, as defined in SEQ ID NO:2, is threonine, whereby to predict an increased likelihood of response to the RET drug.

25 In one embodiment, there is provided a method for predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, comprising determining whether the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO:1: position 105, is cytosine, or at the following position as defined in SEQ ID NO:2: position 918, is threonine, whereby to predict
30 an increased likelihood of response to a RET drug.

In one embodiment the present invention is particularly suitable for use in predicting the response of a patient, who is a candidate for treatment with a RET drug, to a RET drug, in

-5-

patients with a tumour which is dependent alone, or in part, on RET. In one embodiment the present invention is particularly suitable for use in predicting the response to a RET drug, in patients with a tumour which is dependent alone, or in part, on mutant RET. Such tumours include, for example, thyroid carcinomas. In another embodiment the present invention is particularly suitable for use in predicting the response to a RET drug, in patients with a tumour selected from medullary thyroid carcinoma, an adrenal gland tumour (such as phaeochromocytoma) lung cancer (especially small cell lung cancer), papillary thyroid carcinoma, mesothelioma and colorectal cancer. In another embodiment the present invention is particularly suitable for use in predicting the response to a RET drug, in patients with a tumour selected from medullary thyroid carcinoma, an adrenal gland tumour (such as phaeochromocytoma) and lung cancer (especially small cell lung cancer).

In another embodiment the present invention is particularly suitable for use in predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, in patients with a tumour which is dependent alone, or in part, on RET. In one embodiment the present invention is particularly suitable for use in predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, in patients with a tumour which is dependent alone, or in part, on mutant RET. Such tumours include, for example, thyroid carcinomas. In another embodiment the present invention is particularly suitable for use in predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, in patients with a tumour selected from medullary thyroid carcinoma, an adrenal gland tumour (such as phaeochromocytoma) lung cancer (especially small cell lung cancer), papillary thyroid carcinoma, mesothelioma and colorectal cancer. In another embodiment the present invention is particularly suitable for use in predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, in patients with a tumour selected from medullary thyroid carcinoma, an adrenal gland tumour (such as phaeochromocytoma) and lung cancer (especially small cell lung cancer).

In one embodiment of the invention there is provided a method as described hereinabove wherein the method for detecting a nucleic acid mutation in RET and thereby determining the sequence of RET, is selected from sequencing, WAVE analysis, amplification refractory mutation system (ARMS) and restriction fragment length polymorphism (RFLP). ARMS is described in European Patent, Publication No. 0332435,

-6-

the contents of which are incorporated herein by reference, which discloses and claims a method for the selective amplification of template sequences which differ by as little as one base, which method is now commonly referred to as ARMS. RFLP is described by Zhong (Zhong et al. 2006 Clinica Chimica Acta: 364, 205-208). In one embodiment of the invention there is provided a method as described hereinabove wherein the method for determining the sequence of RET in a sample obtained from a patient is selected from any one of amplification refractory mutation system, restriction fragment length polymorphism or WAVE analysis. In one embodiment of the invention there is provided a method as described hereinabove wherein the method for determining the sequence of RET in a sample obtained from a patient is the amplification refractory mutation system. In one embodiment ARMS may comprise use of an agarose gel, sequencing gel or real-time PCR. In one embodiment ARMS comprises use of real-time PCR. The ARMS assay may be multiplexed with a second PCR reaction that detects the presence of DNA in the reaction, thereby indicating successful PCR. TaqMan™ technology may be used to detect the PCR products of both reactions using TaqMan™ probes labelled with different fluorescent tags. The advantages of using ARMS rather than sequencing or RFLP to detect mutations are that ARMS is a quicker single step assay, less processing and data analysis is required, and ARMS can detect a mutation in a sample against a background of wild type polynucleotide.

In one embodiment of the invention there is provided a method of determining the sequence of RET in a sample obtained from a patient comprising use of an ARMS mutant forward primer capable of recognising the sequence of RET at position 105 as shown in SEQ ID NO:1. In one embodiment of the invention there is provided a method of determining the sequence of RET in a sample obtained from a patient comprising use of an ARMS mutant forward primer and an ARMS reverse primer optimized to amplify the region of a RET sequence comprising position 105 as shown in SEQ ID NO:1. The skilled person would understand that "optimized to amplify" comprises determining the most appropriate length and position of the forward primer and reverse primer. In one embodiment the ARMS mutant forward primer and the ARMS reverse primer are optimized to amplify a region of less than 500 bases. In one embodiment the ARMS mutant forward primer and the ARMS reverse primer are optimized to amplify a region of less than 250 bases. In one embodiment the ARMS mutant forward primer and the ARMS reverse primer are optimized to amplify a region of less than 200 bases. In one embodiment the ARMS mutant forward primer and the

ARMS reverse primer are optimized to amplify a region of greater than 100 bases.

In one embodiment the ARMS mutant forward primer is capable of recognising the sequence of RET at position 105 as defined in SEQ ID NO: 1. In one embodiment the ARMS mutant forward primer comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 5 98% or 99% identical to the sequence disclosed in SEQ ID NO:3. In another embodiment the ARMS mutant forward primer comprises SEQ ID NO:3. In a further embodiment the ARMS mutant forward primer consists of SEQ ID NO:3.

In one embodiment the ARMS reverse primer comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID 10 NO:4. In one embodiment the ARMS reverse primer comprises SEQ ID NO:4. In one embodiment the ARMS reverse primer consists of SEQ ID NO:4.

Locked Nucleic Acid (LNA) oligonucleotides contain a methylene bridge connecting the 2'-oxygen of ribose with the 4'-carbon. This bridge results in a locked 3'-endo conformation, reducing the conformational flexibility of the ribose and increasing the local 15 organisation of the phosphate backbone. Braasch and Corey have reviewed the properties of LNA/DNA hybrids (Braasch and Corey, 2001, Chemistry & Biology 8,1-7).

Several studies have shown that primers comprising LNAs have improved affinities for complementary DNA sequences. Incorporation of a single LNA base can allow melting temperatures (T_m) to be raised by up to 41°C when compared to DNA:DNA complexes of the 20 same length and sequence, and can also raise the T_m values by as much as 9.6°C. Braasch and Corey propose that inclusion of LNA bases will have the greatest effect on oligonucleotides shorter than 10 bases.

Implications of the use of LNA for the design of PCR primers have been reviewed (Latorra, Arar and Hurley, 2003, Molecular and Cellular Probes 17, 253-259). It was noted 25 that firm primer design rules had not been established but that optimisation of LNA substitution in PCR primers was complex and depended on number, position and sequence context. Ugozoli et al (Ugozoli, Latorra, Pucket, Arar and Hamby, 2004, Analytical Biochemistry 324, 143-152) described the use of LNA probes to detect SNPs in real-time PCR using the 5' nuclease assay. Latorra et al (Latorra, Campbell, Wolter and Hurley, 2003, 30 Human Mutation 22, 79-85) synthesised a series of primers containing LNA bases at the 3' terminus and at positions adjacent to the 3' terminus for use as allele specific primers. Although priming from mismatched LNA sequences was reduced relative to DNA primers,

optimisation of individual reactions was required.

In one embodiment the ARMS mutant forward primer comprises a sequence in which one or more of the standard DNA bases have been substituted with a LNA base. In one embodiment the ARMS mutant forward primer comprises a sequence at least 75%, 80%,
5 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID NO:9. In another embodiment the ARMS mutant forward primer comprises SEQ ID NO:9. In a further embodiment the ARMS mutant forward primer consists of SEQ ID NO:9.

In one embodiment there is provided an ARMS probe capable of binding to the amplification product resulting from use of an ARMS mutant forward primer and an ARMS
10 reverse primer as described hereinabove in an ARMS assay. In one embodiment the ARMS probe comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID NO:5. In another embodiment the ARMS probe comprises SEQ ID NO:5. In a further embodiment the ARMS probe consists of SEQ ID NO:5. In one embodiment the ARMS probe comprises a sequence in which one or more
15 of the standard DNA bases have been substituted with a LNA base. In one embodiment the ARMS probe comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID NO:10. In another embodiment the ARMS probe comprises SEQ ID NO:10. In a further embodiment the ARMS probe consists of SEQ ID NO:10. In one embodiment the ARMS probe comprises a Yakima YellowTM
20 fluorescent tag on the 5' end. In one embodiment the ARMS probe comprises a BHQTM quencher on the 3' end. The skilled person would recognise that the position at which the probe binds in the amplified product (and thus the sequence of the probe is complementary to) is restricted only by the boundaries imposed by the forward and reverse primers which determine the amplified product.

25 The Control probe is used to confirm that the ARMS assay is working as intended and to confirm that there is DNA in the sample used in the ARMS assay. The skilled person would understand that the Control probe could be targeted to any chosen gene. In one embodiment the Control forward primer comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID NO:6. In
30 another embodiment the Control forward primer primer comprises SEQ ID NO:6. In a further embodiment the Control forward primer primer consists of SEQ ID NO:6. In one embodiment the Control reverse primer comprises a sequence at least 75%, 80%, 85%, 90%,

-9-

95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID NO:7. In another embodiment the Control reverse primer comprises SEQ ID NO:7. In a further embodiment the Control reverse primer consists of SEQ ID NO:7. In one embodiment the Control probe comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID NO:8. In another embodiment the Control probe comprises SEQ ID NO:8. In a further embodiment the Control probe consists of SEQ ID NO:8. In one embodiment the Control probe comprises a sequence in which one or more of the standard DNA bases have been substituted with a LNA base. In one embodiment the Control probe comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence disclosed in SEQ ID NO:11. In another embodiment the Control probe comprises SEQ ID NO:11. In a further embodiment the Control probe consists of SEQ ID NO:11. In one embodiment the Control probe comprises a CyTM-5 fluorescent tag on the 5' end. In one embodiment the Control probe comprises a ElleQuencherTM quencher on the 3' end.

15

Primer	5' Mod	Primer Sequence	3' Mod	SEQ ID NO.
ARMS Mutant Forward Primer		CTTTAG <u>T</u> GTCGGATTCCAGTTAAATGG <u>T</u> C		3
ARMS LNA Mutant Forward Primer		T+CGG+ATT+CCA+GT+TAAATGG <u>T</u> +C		9
ARMS Reverse Primer Short		TGCAATTCCTGGCCAAGCTGC		4
ARMS Probe	Yakima Yellow TM	CTACACCACGCAAAGTGATGTGTAAGTGTGGGTGTTGCTC	BHQ TM	5
ARMS LNA Probe	Yakima Yellow TM	TGA+TG+TG+TAAGTGTG+GGTGTG+CTC	BHQ TM	10
Control Primer Forward		AGGACACCGAGGAAGAGGACTT		6

-10-

Primer	5' Mod	Primer Sequence	3' Mod	SEQ ID NO.
Control Primer Reverse		GGAATCACCTTCTGTCTTCATT		7
Control Probe	Cy TM -5	CCATCTTCTTCCTGCCTGATGAGGGGAAA	ElleQuencher	8
Control LNA Probe	Cy TM -5	CTGC+CT+GA+TGAGGGGAA	ElleQuencher	11

Table 1 ARMS Assay Primers and Probes

The control gene is α 1 antitrypsin. Yakima Yellow and CyTM-5 are fluorescent tags and
 5 BHQTM (Black Hole QuencherTM) and ElleQuencher are quenchers.
 Emboldened underlined bases indicate mismatch positions. LNA substitution indicated by '+'
 e.g. +C, +A, +T and +G.

In another aspect of the invention there is provided a method as described hereinabove
 10 wherein the method for determining the sequence of RET comprises determining the
 sequence of cDNA generated by reverse transcription of RET mRNA extracted from archival
 tumour sections or other clinical material. Extraction of RNA from formalin fixed tissue has
 been described in Bock et al., 2001 Analytical Biochemistry: 295 116-117, procedures for
 extraction of RNA from non-fixed tissues, and protocols for generation of cDNA by reverse
 15 transcription, PCR amplification and sequencing are described in Sambrook, J. and Russell,
 D.W., Molecular Cloning: A Laboratory Manual, the third edition, Cold Spring Harbor
 Laboratory Press, Cold Spring Harbor, New York, 2001.

In another aspect of the invention there is provided a method as described hereinabove
 wherein the method for determining the sequence of RET comprises amplification of
 20 individual exons of the RET gene, heteroduplex annealing of individual exons followed by
 digestion with Cel I (as described in Crepin et al., 2006 Endocrinology: 36, 369-376; and
 Marsh et al., 2001 Neoplasia: 3, 236-244).

In another aspect, the invention provides a mutant human RET polynucleotide
 comprising the following nucleic acid base at the following position as defined in SEQ ID

-11-

NO: 1: a cytosine at position 105, or a fragment thereof comprising at least 20 nucleic acid bases provided that the fragment comprises position 105.

In a further aspect the invention provides a mutant human RET polypeptide comprising the following amino acid residue at the following position as defined in SEQ ID

5 NO: 2: a threonine at position 918, or a fragment thereof comprising at least 10 amino acid residues provided that the fragment comprises position 918.

In another aspect, there is provided a method for determining the sequence of RET in mRNA encoded by a mutant RET gene.

In another aspect of the invention there is provided a method as described herein
10 wherein the method for determining the sequence of RET is selected from, for example, an immunohistochemistry-based assay which may use a slide from a single patient, or a tissue microarray (Mayr et al., 2006 American Journal of Clinical Pathology: 126, 101-109; Zheng et al., 2006 Anticancer Research: 26, 2353-2360) or application of an alternative proteomics methodology, which could comprise lysing cells, digesting the proteins, separating protein
15 fragments on a gel, obtaining the peptide containing the mutated amino acid and analysing the peptide by mass spectrometry.

In another aspect the invention provides an antibody specific for a mutant human RET polypeptide as defined hereinabove.

A further aspect of the invention provides a diagnostic kit, comprising an ARMS
20 mutant forward primer capable of detecting a mutation in RET at position 105, as defined in SEQ ID NO: 1, and optionally an ARMS reverse primer, and optionally instructions for use. In one embodiment of the invention there is provided a diagnostic kit, comprising an ARMS mutant forward primer comprising one or more LNA bases and capable of recognising the sequence of RET at position 105, as defined in SEQ ID NO: 1, and optionally an ARMS
25 reverse primer, and optionally instructions for use. In one embodiment the diagnostic kit may be used in a method of predicting the likelihood that a patient, who is a candidate for treatment with a RET drug, will respond to said treatment. In an alternative embodiment the diagnostic kit may be used in selecting a patient, who is a candidate for treatment with a RET drug, for said treatment. In an alternative embodiment the diagnostic kit may be used to
30 assess the suitability of a patient, who is a candidate for treatment with a RET drug, for said treatment.

-12-

A further aspect of the invention provides a diagnostic kit, comprising an antibody specific for a mutant human RET polypeptide as defined hereinabove, and optionally instructions for use. In one embodiment the diagnostic kit may be used in a method of predicting the likelihood that a patient, who is a candidate for treatment with a RET drug, will respond to said treatment. In an alternative embodiment the diagnostic kit may be used in selecting a patient, who is a candidate for treatment with a RET drug, for said treatment. In an alternative embodiment the diagnostic kit may be used to assess the suitability of a patient, who is a candidate for treatment with a RET drug, for said treatment.

In a further aspect of the invention the ARMS primers and probes as described hereinabove may be used to determine the sequence of RET in a panel of cell lines expressing either the wild type or a mutant RET. Knowledge of whether the cell lines are expressing either wild type or mutant RET could be used in screening programmes to identify novel RET inhibitors with specificity for the mutant RET phenotype or novel inhibitors with activity against the phenotype associated with the wild type receptor. The availability of a panel of cell lines expressing mutant RETs will assist in the definition of the signaling pathways activated through RET and may lead to the identification of additional targets for therapeutic intervention.

In another aspect the invention provides a method of preparing a personalised genomics profile for a patient comprising determining the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 1: position 105, and/or the following position as defined in SEQ ID NO: 2: position 918, and creating a report summarising the data obtained by said analysis.

In a specific embodiment, the method as described hereinabove may be used to assess the pharmacogenetics of a RET drug. Pharmacogenetics is the study of genetic variation that gives rise to differing response to drugs. By determining the sequence of RET in a sample obtained from a patient and analysing the response of the patient to a RET drug, the pharmacogenetics of the RET drug can be elucidated.

In one embodiment the method for predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, may be used to select a patient, or patient population, with a tumour for treatment with a RET drug.

In one embodiment the method for predicting the likelihood that a patient who is a candidate for treatment with a RET drug will respond to said treatment, may be used to

-13-

predict the responsiveness of a patient, or patient population, with a tumour to treatment with a RET drug.

The sample obtained from the patient may be any tumour tissue or any biological sample that contains material which originated from the tumour, for example a blood sample containing circulating tumour cells or DNA. In one embodiment the blood sample may be whole blood, plasma, serum or pelleted blood. In one embodiment a tumour sample is a tumour tissue sample. The tumour tissue sample may be a fixed or unfixed sample. In another embodiment the biological sample would have been obtained using a minimally invasive technique to obtain a small sample of tumour, or suspected tumour, from which to determine the RET sequence. In another embodiment the biological sample comprises either a single sample, which may be tested for any of the mutations as described hereinabove, or multiple samples, which may be tested for any of the mutations as described hereinabove.

According to another aspect of the invention there is provided a method of using the results of the methods described above in determining an appropriate dosage of a RET drug. For example, knowledge that a patient is predicted to have an increased likelihood of response to a RET drug, could be used in determining an appropriate dosage of the RET drug. Calculating therapeutic drug dose is a complex task requiring consideration of medicine, pharmacokinetics and pharmacogenetics. The therapeutic drug dose for a given patient will be determined by the attending physician, taking into consideration various factors known to modify the action of drugs including severity and type of disease, body weight, sex, diet, time and route of administration, other medications and other relevant clinical factors. Therapeutically effective dosages may be determined by either *in vitro* or *in vivo* methods.

A RET drug is a RET inhibitor. A RET inhibitor is an agent that inhibits the activity of RET. Said agent may be an antibody or a small molecule. In one embodiment a RET inhibitor is a RET tyrosine kinase inhibitor. A RET inhibitor may have activity against other proteins, such as inhibition of the activity of other tyrosine kinases, for example VEGFR2 and/or EGFR. In one embodiment a RET inhibitor also inhibits EGFR tyrosine kinase activity. In one embodiment a RET inhibitor also inhibits VEGFR2 tyrosine kinase activity. In one embodiment a RET inhibitor also inhibits VEGFR2 and EGFR tyrosine kinase activity. RET, EGFR or VEGFR2 tyrosine kinase inhibitors include vandetanib, cediranib (AZD2171, Recentin™, (Wedge et al., 2005 Cancer Research: 65, 4389-4400)), gefitinib, erlotinib, sunitinib (SU11248, Sutent®, Pfizer), SU14813 (Pfizer), vatalanib (Novartis),

-14-

sorafenib (BAY43-9006, Nexavar, Bayer), XL-647 (Exelixis), XL-999 (Exelixis), AG-013736 (Pfizer), motesanib (AMG706, Amgen), BIBF1120 (Boehringer), TSU68 (Taiho), GW786034, AEE788 (Novartis), CP-547632 (Pfizer), KRN 951 (Kirin), CHIR258 (Chiron), CEP-7055 (Cephalon), OSI-930 (OSI Pharmaceuticals), ABT-869 (Abbott), E7080 (Eisai),
5 ZK-304709 (Schering), BAY57-9352 (Bayer), L-21649 (Merck), BMS582664 (BMS), XL-880 (Exelixis), XL-184 (Exelixis) or XL-820 (Exelixis).

In one embodiment the RET inhibitor is selected from vandetanib, cediranib, sunitinib, motesanib or an antibody. In one embodiment the RET inhibitor is vandetanib. In one embodiment the RET inhibitor is cediranib. In one embodiment the RET inhibitor is
10 motesanib. In one embodiment the RET inhibitor is sunitinib. In one embodiment the RET inhibitor is an antibody.

An effective amount of a RET drug will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it is preferred for the therapist to titer the dosage and modify the route of administration as
15 required to obtain the optimal therapeutic effect. A typical daily or intermittent dosage, such as weekly, fortnightly or monthly, might range from about 0.5mg to up to 300mg, 500mg, 1000mg or 1200 mg or more, depending on the factors mentioned above.

We contemplate that a RET drug may be used as monotherapy or in combination with other drugs. The present invention is also useful in adjuvant, or as a first-line, therapy.

20 In one embodiment the method of the present invention additionally comprises administration of a RET drug to a patient selected for, or predicted to respond to treatment with a RET drug according the methods described hereinabove.

In one embodiment of the invention there is provided use of a RET drug in preparation of a medicament for treating a patient, or a patient population, selected for, or predicted to
25 respond to, treatment with a RET drug according the methods described hereinabove.

In one embodiment of the invention there is provided a method of treating a patient, or a patient population, selected for, or predicted to have an increased likelihood of response to a RET drug according to the method as described herein, comprising administering a RET drug to said patient(s).

30 In one embodiment of the invention there is provided a method of treating a patient who is a candidate for treatment with a RET drug comprising:

-15-

- (i) determining whether the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 1: position 105, is not thymine; or
(ii) determining whether the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 2: position 918, is not methionine;
5 and administering an effective amount of the RET drug.

In one embodiment of the invention there is provided a method of treating a patient who is a candidate for treatment with a RET drug comprising:

- (i) determining whether the sequence of RET in a sample obtained from the patient at position 105, as defined in SEQ ID NO: 1, is not thymine; or
10 (ii) determining whether the sequence of RET in a sample obtained from the patient at position 918, as defined in SEQ ID NO: 2, is not methionine;
and administering an effective amount of the RET drug.

In one embodiment of the invention there is provided a method of treating a patient who is a candidate for treatment with a RET drug, comprising:

- 15 (i) determining whether the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 1: position 105, is cytosine; or
(ii) determining whether the sequence of RET in a sample obtained from the patient at the following position as defined in SEQ ID NO: 2: position 918, is threonine,
and administering an effective amount of the RET drug.

20 In one embodiment of the invention there is provided a method of treating a patient who is a candidate for treatment with a RET drug comprising:

- (i) determining whether the sequence of RET in a sample obtained from the patient at position 105, as defined in SEQ ID NO: 1, is cytosine; or
(ii) determining whether the sequence of RET in a sample obtained from the patient at
25 position 918, as defined in SEQ ID NO: 2, is threonine;
and administering an effective amount of the RET drug.

Examples

30 The invention is illustrated by the following non-limiting examples, in which

Figure 1. Shows detection of M918T RET mutation using conventional DNA ARMS primers. The open diamonds show the signal obtained with 1000 copies of mutant DNA,

-16-

black squares show the signal obtained with 10000 copies of wild type DNA, and black diamonds show the signal obtained with 1000 copies of wild type DNA.

Figure 2. Shows detection of M918T RET mutation using LNA modified ARMS primers. The black triangles show the signal obtained with 1000 copies of mutant DNA, black squares show the signal obtained with 1000 copies of wild type DNA, and black circles show the signal obtained with 10000 copies of wild type DNA.

General molecular biology techniques are described in "Current Protocols in Molecular Biology Volumes 1-3, edited by F M Asubel, R Brent and R E Kingston; published by John Wiley, 1998 and Sambrook, J. and Russell, D.W., Molecular Cloning: A Laboratory Manual, the third edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001.

Example 1 – Identification of mutations in sporadic medullary thyroid tumour sections

Tumour sections were taken from patients at the time of diagnosis or surgery. The sections were formalin fixed and embedded in paraffin wax. The prepared samples were cut into sections, which varied in thickness from 5-20 microns. Regions of section containing tumour were identified by histopathology of a master slide and tumour material was recovered from the relevant area of adjacent slides cut from the same tumour sample, as described by Lynch et al. 2004 New England Journal of Medicine: 350 2129-2139. Other types of tumour sample could include for example, fresh or frozen tissue or circulating tumour cells. Details of techniques using such samples may be found in Sambrook, J. and Russell, D.W., Molecular Cloning: A Laboratory Manual, the third edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001.

Example 2 - DNA extraction from slide section

Volumes are given for extraction of one section. Regions of tumour identified by histopathology on one section were isolated from adjacent sections by scraping relevant area from slide into an eppendorf tube. The material from a 20micron section was resuspended in

-17-

100µl 0.5% Tween-20 (Sigma Aldrich), heated to 90°C for 10 minutes then cooled to 55°C. Proteinase K (2µl, 10mg/ml) was added to the suspension, the solution was mixed and incubated at 55°C for 3 hours with occasional mixing. Chelex-100™ (C7901, Sigma) (100µl, 5% (w/v) in Tris EDTA) was added and the suspension was incubated at 99°C for 10 minutes.

5 The extracted DNA was recovered by centrifugation at 10500 x g for 15 minutes, the solution below the wax layer which formed was transferred to a clean tube. The solution was heated to 45°C before adding chloroform (100µl). The suspension was mixed before further centrifugation at 10500 x g for 15 minutes, DNA was then recovered from the upper aqueous layer by ethanol precipitation. The DNA pellet was rinsed in 70% ethanol, recovered by a

10 pulse of centrifugation, air dried and dissolved in water (50µl).

Example 3 – Amplification Refractory Mutation System for detection of Met918Thr mutation in RET using ARMS primers

15 An Amplification Refractory Mutation System assay (ARMS) may be used to detect the presence of a nucleotide base change in the RET gene compared to a background of normal DNA. Each ARMS assay is specific for a given mutation e.g. designed to detect a change from one base to another base at a given position. The assay is multiplexed with a second PCR reaction that detects the presence of DNA in the reaction, thereby indicating

20 successful PCR. TaqMan™ technology is used to detect the PCR products of both reactions using TaqMan™ probes labelled with different fluorescent tags.

PCR was performed on 5µl of genomic DNA containing varying proportions of mutant and wild type DNA and varying concentrations of input DNA. A total reaction volume of 25 µl was used for each PCR. 1 Unit of Amplitaq gold DNA polymerase

25 (N80080246, ABI) was used in each reaction with final concentrations of 3.5 mM magnesium chloride, 200µM dNTPs (deoxyribonucleotide triphosphates) and 1.0 µM of each ARMs mutant forward primer and ARMS reverse primer short (see Table 1) in buffer (final buffer composition 15 mM Tris-HCl Ph 8.3, 50 mM KCl). TaqMan™ probes (Eurogentech) were added to each reaction at a final concentration of 0.5 µM. Cycle conditions were as follows:

30 95°C for 10 minutes followed by 40 cycles of 94°C for 45 seconds, 60°C for 45 seconds,

-18-

72°C for 1 minute in a Real Time PCR instrument (e.g. Stratagene Mx4000 or ABI 7900). 10 copies of mutant could be detected in a background of 1000 copies of wild type DNA.

5 *Example 4 – Amplification Refractory Mutation System for detection of Met918Thr mutation in RET from Clinical Samples using ARMS LNA primers*

Formalin fixed tissue samples were obtained from patients participating in a clinical trial to assess the activity of vandetanib in sporadic medullary thyroid cancer.

10 DNA was extracted as described in Example 2. Nineteen samples were available for analysis, including two samples from a single patient. All samples were analysed in triplicate and scored by two independent operators.

An Amplification Refractory Mutation System assay (ARMS) was used to detect the presence of a nucleotide base change in the RET gene compared to a background of normal DNA. The assay was multiplexed with a second PCR reaction that detects the presence of
15 DNA in the reaction, thereby indicating successful PCR. TaqMan™ technology was used to detect the PCR products of both reactions using TaqMan™ probes labelled with different fluorescent tags.

PCR was performed on genomic DNA containing varying proportions of mutant and wild type DNA and varying concentrations of input DNA. A total reaction volume of 25 µl
20 was used for each PCR. 1 Unit of Amplitaq gold DNA polymerase was used in each reaction with final concentrations of 3.5 mM magnesium chloride, 200µM dNTPs and 1.0 µM of each ARMS LNA Mutant Forward primer and ARMS Reverse Primer Short (see Table 1) in buffer (final buffer composition 15 mM Tris-HCl Ph 8.3, 50 mM KCl). TaqMan™ probes were added to each reaction at a final concentration of 0.5 µM. Cycle conditions were as follows:
25 95°C for 10 minutes followed by 40 cycles of 94°C for 45 seconds, 60°C for 1 minute, 72°C for 45 seconds in a Real Time PCR instrument (e.g. Stratagene Mx4000 or ABI 7900).

Six samples could not be scored because of low DNA concentrations. Mutations were detected in 8/13 of the evaluable samples, giving a mutation frequency of 61.5%. Sequencing was performed on all samples to confirm mutation status; but sequence data could only be
30 obtained from samples with DNA concentrations >50 copies and thus only 4 samples gave readable sequence at codon 918. The results obtained by sequencing were fully concordant with the data from the ARMS assay.

Sample Identifier	DNA copies	Mutation status	Sequence Confirmation
E2802001	<5	Assay fail	
E1701004	<5	Assay fail	
E1701003	<5	Assay fail	
E1001001	<5	Assay fail	
E0002001-a	<5	Assay fail	
E0002004	<5	Assay fail	
E2801001	<5	Mutant	
E0002005	170	Mutant	Yes
E2002002	240	Mutant	Yes
E2002001	<5	Mutant	
E1001002	<5	Mutant	
E1001004	<5	Mutant	
E0002001-b	<5	Mutant	
E0002002	430	Mutant	
E0011003	410	Wild-type	Yes
E1707002	120	Wild-type	Yes
E3001001	90	Wild-type	
E1201002	<5	Wild-type	
E0002003	10	Wild-type	

Table 2 Mutation Detection in Clinical Samples

5 Two samples (-a, -b) were obtained from patient E0002001

Example 5 – Comparison of specificity of conventional DNA primers compared to LNA primers in an ARMS assay to detect the M918T RET mutation

10 An experiment was performed to determine the threshold at which ARMS primers designed to detect the M918T RET mutation can generate a signal from wild type DNA. PCR was performed on 5µl of either mutant or wild type genomic DNA representing different concentrations of input DNA. A total reaction volume of 25 µl was used for each PCR. 1

-20-

Unit of Amplitaq gold DNA polymerase was used in each reaction with final concentrations of 3.5 mM magnesium chloride, 200µM dNTPs and 1.0 µM of each ARMs mutant forward primer and ARMS reverse primer short (see Table 1) in buffer (final buffer composition 15 mM Tris-HCl Ph 8.3, 50 mM KCl). TaqMan™ probes were added to each reaction at a final concentration of 0.5 µM. Cycle conditions were as follows: 95°C for 10 minutes followed for up to 45 cycles of 94°C for 45 seconds, 60°C for 45 seconds, 72°C for 1 minute in a Real Time PCR instrument (e.g. Stratagene Mx4000 or ABI 7900).

A signal is generated from 1000 copies of mutant DNA at 29 cycles using the conventional DNA ARMS primers (Figure 1). However, a signal is also generated from a sample containing either 1000 or 10000 copies of wild type DNA. Although the signal from wild type DNA is generated at 35 and 32 cycles respectively, the potential to obtain a signal from wild type DNA could limit the use of conventional DNA ARMS primers in the clinical setting where it is common for fixed tumour samples to contain mixtures of normal and tumour tissue.

A similar experiment was performed using LNA modified primers. In this experiment, a signal is generated from the sample containing 1000 copies of mutant DNA at 31 cycles but no signal is generated from the samples containing either 1000 or 10000 copies of wild type DNA even when the analysis is extended to 45 cycles (Figure 2).

Example 6 – Selection of patients for treatment

Detection of a mutation in the RET gene in a tumour sample can be used to improve the selection of a patient who is a candidate for treatment with vandetanib or other inhibitors of the RET tyrosine kinase, either as monotherapy or in combination therapy, whereby to predict an increased likelihood of response to vandetanib or other inhibitors of the RET tyrosine kinase.

Claims

1. A method for predicting the likelihood that a patient who is a candidate for treatment with a RET tyrosine kinase inhibitor will respond to said treatment, comprising determining whether the sequence of RET in a sample obtained from the patient
 - at position 105, as defined in SEQ ID NO:1, is not thymine; or
 - at position 918, as defined in SEQ ID NO:2, is not methionine,whereby to predict an increased likelihood of response to the RET tyrosine kinase inhibitor.
2. A method according to claim 1 wherein
 - position 105 is cytosine; or
 - position 918 is threonine.
3. A method according to claim 1 or 2 wherein position 105 is cytosine.
4. Use of a RET tyrosine kinase inhibitor in the preparation of a medicament for treating a patient, or patient population, selected for, or predicted to respond to, treatment with a RET tyrosine kinase inhibitor according to any one of claims 1 to 3.
5. A method according to claim 3 or use according to claim 4, wherein the method for determining the sequence of RET in a sample obtained from a patient is selected from any one of amplification refractory mutation system, restriction fragment length polymorphism or WAVE analysis.
6. A method according to claim 3 or 5 or use according to claim 4, 5 wherein the method for determining the sequence of RET in a sample obtained from a patient is the amplification refractory mutation system.
7. A method according to claim 3, 5 or 6, or a use according to claim 4, comprising using an ARMS mutant forward primer capable of recognizing the sequence of RET at position 105, as defined in SEQ ID NO: 1.

8. A method according to claim 3, 5, 6 or 7, or a use according to claim 4, comprising using an ARMS mutant forward primer and an ARMS reverse primer optimized to amplify the region of a RET sequence comprising position 105, as defined in SEQ ID NO: 1.
9. A method according to claim 7 or 8, wherein the ARMS mutant forward primer comprises SEQ ID NO:9.
10. A method according to any one of claims 1 to 3, or 5 to 9, or a use according to claim 4, wherein the RET tyrosine kinase inhibitor is selected from:
(i) vandetanib, or (ii) cediranib.
11. A method according to any one of claims 1 to 3, or 5 to 10, or a use according to claim 4, wherein the patient has a tumour selected from medullary thyroid carcinoma, an adrenal gland tumour, lung cancer, papillary thyroid carcinoma, mesothelioma and colorectal cancer.

102477

1

SEQUENCE LISTING

<110> AstraZeneca AB

<120> Method

<130> 102477 CCH Aug07

<160> 11

<170> PatentIn version 3.4

<210> 1

<211> 320

<212> DNA

<213> Homo Sapiens

<400> 1
 gatagggcct ggccttctcc ttaccctc ctccctagag agttagagta acttcaatgt 60
 ctttattcca tcttctcttt agggctcgat tccagttaaa tggatggcaa ttgaatccct 120
 ttttgatcat atctacacca cgcaaagtga tgtgtaagtg tgggtgttgc tctcttgggg 180
 tggaggttac agaaacaccc ttatacatgt agtggggcca cgacgcccgt ctgtgcagct 240
 tggccagga attgcactgg ccctgagcac ctgtctgcag tgctagccct ctgcaatgac 300
 ccctcactg aggggccttc 320

<210> 2

<211> 1114

<212> PRT

<213> Homo Sapiens

<400> 2

Met Ala Lys Ala Thr Ser Gly Ala Ala Gly Leu Arg Leu Leu Leu Leu
 1 5 10 15

Leu Leu Leu Pro Leu Leu Gly Lys Val Ala Leu Gly Leu Tyr Phe Ser
 20 25 30

Arg Asp Ala Tyr Trp Glu Lys Leu Tyr Val Asp Gln Ala Ala Gly Thr
 35 40 45

Pro Leu Leu Tyr Val His Ala Leu Arg Asp Ala Pro Glu Glu Val Pro
 50 55 60

Ser Phe Arg Leu Gly Gln His Leu Tyr Gly Thr Tyr Arg Thr Arg Leu
 65 70 75 80

His Glu Asn Asn Trp Ile Cys Ile Gln Glu Asp Thr Gly Leu Leu Tyr
 85 90 95

Leu Asn Arg Ser Leu Asp His Ser Ser Trp Glu Lys Leu Ser Val Arg
 100 105 110

Asn Arg Gly Phe Pro Leu Leu Thr Val Tyr Leu Lys Val Phe Leu Ser
 115 120 125

Pro Thr Ser Leu Arg Glu Gly Glu Cys Gln Trp Pro Gly Cys Ala Arg
 130 135 140

102477

2

Val Tyr Phe Ser Phe Phe Asn Thr Ser Phe Pro Ala Cys Ser Ser Leu
145 150 155 160

Lys Pro Arg Glu Leu Cys Phe Pro Glu Thr Arg Pro Ser Phe Arg Ile
165 170 175

Arg Glu Asn Arg Pro Pro Gly Thr Phe His Gln Phe Arg Leu Leu Pro
180 185 190

Val Gln Phe Leu Cys Pro Asn Ile Ser Val Ala Tyr Arg Leu Leu Glu
195 200 205

Gly Glu Gly Leu Pro Phe Arg Cys Ala Pro Asp Ser Leu Glu Val Ser
210 215 220

Thr Arg Trp Ala Leu Asp Arg Glu Gln Arg Glu Lys Tyr Glu Leu Val
225 230 235 240

Ala Val Cys Thr Val His Ala Gly Ala Arg Glu Glu Val Val Met Val
245 250 255

Pro Phe Pro Val Thr Val Tyr Asp Glu Asp Asp Ser Ala Pro Thr Phe
260 265 270

Pro Ala Gly Val Asp Thr Ala Ser Ala Val Val Glu Phe Lys Arg Lys
275 280 285

Glu Asp Thr Val Val Ala Thr Leu Arg Val Phe Asp Ala Asp Val Val
290 295 300

Pro Ala Ser Gly Glu Leu Val Arg Arg Tyr Thr Ser Thr Leu Leu Pro
305 310 315 320

Gly Asp Thr Trp Ala Gln Gln Thr Phe Arg Val Glu His Trp Pro Asn
325 330 335

Glu Thr Ser Val Gln Ala Asn Gly Ser Phe Val Arg Ala Thr Val His
340 345 350

Asp Tyr Arg Leu Val Leu Asn Arg Asn Leu Ser Ile Ser Glu Asn Arg
355 360 365

Thr Met Gln Leu Ala Val Leu Val Asn Asp Ser Asp Phe Gln Gly Pro
370 375 380

Gly Ala Gly Val Leu Leu Leu His Phe Asn Val Ser Val Leu Pro Val
385 390 395 400

Ser Leu His Leu Pro Ser Thr Tyr Ser Leu Ser Val Ser Arg Arg Ala
405 410 415

Arg Arg Phe Ala Gln Ile Gly Lys Val Cys Val Glu Asn Cys Gln Ala
420 425 430

102477

3

Phe Ser Gly Ile Asn Val Gln Tyr Lys Leu His Ser Ser Gly Ala Asn
 435 440 445

Cys Ser Thr Leu Gly Val Val Thr Ser Ala Glu Asp Thr Ser Gly Ile
 450 455 460

Leu Phe Val Asn Asp Thr Lys Ala Leu Arg Arg Pro Lys Cys Ala Glu
 465 470 475 480

Leu His Tyr Met Val Val Ala Thr Asp Gln Gln Thr Ser Arg Gln Ala
 485 490 495

Gln Ala Gln Leu Leu Val Thr Val Glu Gly Ser Tyr Val Ala Glu Glu
 500 505 510

Ala Gly Cys Pro Leu Ser Cys Ala Val Ser Lys Arg Arg Leu Glu Cys
 515 520 525

Glu Glu Cys Gly Gly Leu Gly Ser Pro Thr Gly Arg Cys Glu Trp Arg
 530 535 540

Gln Gly Asp Gly Lys Gly Ile Thr Arg Asn Phe Ser Thr Cys Ser Pro
 545 550 555 560

Ser Thr Lys Thr Cys Pro Asp Gly His Cys Asp Val Val Glu Thr Gln
 565 570 575

Asp Ile Asn Ile Cys Pro Gln Asp Cys Leu Arg Gly Ser Ile Val Gly
 580 585 590

Gly His Glu Pro Gly Glu Pro Arg Gly Ile Lys Ala Gly Tyr Gly Thr
 595 600 605

Cys Asn Cys Phe Pro Glu Glu Glu Lys Cys Phe Cys Glu Pro Glu Asp
 610 615 620

Ile Gln Asp Pro Leu Cys Asp Glu Leu Cys Arg Thr Val Ile Ala Ala
 625 630 635 640

Ala Val Leu Phe Ser Phe Ile Val Ser Val Leu Leu Ser Ala Phe Cys
 645 650 655

Ile His Cys Tyr His Lys Phe Ala His Lys Pro Pro Ile Ser Ser Ala
 660 665 670

Glu Met Thr Phe Arg Arg Pro Ala Gln Ala Phe Pro Val Ser Tyr Ser
 675 680 685

Ser Ser Gly Ala Arg Arg Pro Ser Leu Asp Ser Met Glu Asn Gln Val
 690 695 700

Ser Val Asp Ala Phe Lys Ile Leu Glu Asp Pro Lys Trp Glu Phe Pro
 705 710 715 720

102477

4

Arg Lys Asn Leu Val Leu Gly Lys Thr Leu Gly Glu Gly Glu Phe Gly
 725 730 735

Lys Val Val Lys Ala Thr Ala Phe His Leu Lys Gly Arg Ala Gly Tyr
 740 745 750

Thr Thr Val Ala Val Lys Met Leu Lys Glu Asn Ala Ser Pro Ser Glu
 755 760 765

Leu Arg Asp Leu Leu Ser Glu Phe Asn Val Leu Lys Gln Val Asn His
 770 775 780

Pro His Val Ile Lys Leu Tyr Gly Ala Cys Ser Gln Asp Gly Pro Leu
 785 790 795 800

Leu Leu Ile Val Glu Tyr Ala Lys Tyr Gly Ser Leu Arg Gly Phe Leu
 805 810 815

Arg Glu Ser Arg Lys Val Gly Pro Gly Tyr Leu Gly Ser Gly Gly Ser
 820 825 830

Arg Asn Ser Ser Ser Leu Asp His Pro Asp Glu Arg Ala Leu Thr Met
 835 840 845

Gly Asp Leu Ile Ser Phe Ala Trp Gln Ile Ser Gln Gly Met Gln Tyr
 850 855 860

Leu Ala Glu Met Lys Leu Val His Arg Asp Leu Ala Ala Arg Asn Ile
 865 870 875 880

Leu Val Ala Glu Gly Arg Lys Met Lys Ile Ser Asp Phe Gly Leu Ser
 885 890 895

Arg Asp Val Tyr Glu Glu Asp Ser Tyr Val Lys Arg Ser Gln Gly Arg
 900 905 910

Ile Pro Val Lys Trp Met Ala Ile Glu Ser Leu Phe Asp His Ile Tyr
 915 920 925

Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile
 930 935 940

Val Thr Leu Gly Gly Asn Pro Tyr Pro Gly Ile Pro Pro Glu Arg Leu
 945 950 955 960

Phe Asn Leu Leu Lys Thr Gly His Arg Met Glu Arg Pro Asp Asn Cys
 965 970 975

Ser Glu Glu Met Tyr Arg Leu Met Leu Gln Cys Trp Lys Gln Glu Pro
 980 985 990

Asp Lys Arg Pro Val Phe Ala Asp Ile Ser Lys Asp Leu Glu Lys Met
 995 1000 1005

102477

5

Met Val Lys Arg Arg Asp Tyr Leu Asp Leu Ala Ala Ser Thr Pro
 1010 1015 1020

Ser Asp Ser Leu Ile Tyr Asp Asp Gly Leu Ser Glu Glu Glu Thr
 1025 1030 1035

Pro Leu Val Asp Cys Asn Asn Ala Pro Leu Pro Arg Ala Leu Pro
 1040 1045 1050

Ser Thr Trp Ile Glu Asn Lys Leu Tyr Gly Met Ser Asp Pro Asn
 1055 1060 1065

Trp Pro Gly Glu Ser Pro Val Pro Leu Thr Arg Ala Asp Gly Thr
 1070 1075 1080

Asn Thr Gly Phe Pro Arg Tyr Pro Asn Asp Ser Val Tyr Ala Asn
 1085 1090 1095

Trp Met Leu Ser Pro Ser Ala Ala Lys Leu Met Asp Thr Phe Asp
 1100 1105 1110

Ser

<210> 3
 <211> 29
 <212> DNA
 <213> Artificial

<220>
 <223> PCR Primer

<400> 3
 ctttagtggtc ggattccagt taaatggtc

29

<210> 4
 <211> 22
 <212> DNA
 <213> Artificial

<220>
 <223> 22; PCR Primer

<400> 4
 tgcaattccc tggccaagct gc

22

<210> 5
 <211> 40
 <212> DNA
 <213> Artificial

<220>
 <223> PCR Primer

<400> 5
 ctacaccacg caaagtgatg tgtaagtgtg ggtgttgctc

40

<210> 6
 <211> 22

102477

6

<212> DNA
<213> Artificial

<220>
<223> PCR PRIMER

<400> 6
aggacaccga ggaagaggac tt 22

<210> 7
<211> 23
<212> DNA
<213> Artificial

<220>
<223> PCR PRIMER

<400> 7
ggaatcacct tctgtcttca ttt 23

<210> 8
<211> 29
<212> DNA
<213> Artificial

<220>
<223> PCR PRIMER

<400> 8
ccatcttctt cctgcctgat gaggggaaa 29

<210> 9
<211> 21
<212> DNA
<213> Artificial

<220>
<223> PCR PRIMER

<400> 9
tcggattcca gttaaattgt c 21

<210> 10
<211> 25
<212> DNA
<213> PCR Primer

<400> 10
tgatgtgtaa gtgtgggtgt tgctc 25

<210> 11
<211> 17
<212> DNA
<213> Artificial

<220>
<223> PCR PRIMER

<400> 11
ctgcctgatg aggggaa 17